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This is an open-access article distributed under the terms of the Creative Commons 
Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is 
permissible to download and share the work provided it is properly cited. The work cannot 
be changed in any way or used commercially without permission from the journal. 
 5 
Abstract 
Levosimendan is an inodilator that promotes cardiac contractility primarily via calcium 
sensitization of cardiac troponin C and vasodilatation via opening of adenosine triphosphate-
sensitive potassium (KATP) channels in vascular smooth muscle cells; the drug also exerts organ-
protective effects via a similar effect on mitochondrial KATP channels. 10 
This pharmacological profile identifies levosimendan as a drug that may have applications in a 
wide range of critical illness situations encountered in intensive care unit medicine: 
hemodynamic support in cardiogenic or septic shock; weaning from mechanical ventilation or 
from extracorporeal membrane oxygenation; and in the context of cardiorenal syndrome. 
This review, authored by experts from 9 European countries (Austria, Belgium, Czech republic, 15 
Finland, France, Germany, Italy, Sweden, and Switzerland) examines the clinical and 
experimental data for levosimendan in these situations and concludes that, in most instances, the 
evidence is affirmative and encouraging, which is not the case with other cardio- and vasoactive 
drugs routinely used in the intensive care unit. The size of the available studies is, however, 
limited and the data are in need of verification in larger controlled trials. Some proposals are 20 
offered for the aims and designs of these additional studies.  
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mechanical ventilation; extracorporeal membrane oxygenation; cardiorenal syndrome 
 
1. The calcium sensitizer levosimendan 
Levosimendan is a positive inotropic compound with vasodilatory properties [1] used for the 5 
treatment of acute decompensated heart failure (HF), and in cases where the use of an inotropic 
treatment is considered appropriate [2]. The principal mechanism of levosimendan is the 
sensitization of troponin C to calcium in cardiac muscle [3–5], which leads to its unique feature 
of exerting a positive inotropic effect without increasing myocardial oxygen consumption [6–
10]. In addition, levosimendan opens adenosine triphosphate-sensitive potassium (KATP) 10 
channels in vascular smooth muscle cells [11,12] and induces vasodilation of the pulmonary 
[13], coronary [14,15] and peripheral arteries [16] and of the venous circulation [17] . By 
addressing both cardiac inotropy and vascular dilatation, levosimendan improves cardiovascular 
coupling and cardiac mechanical efficiency. Levosimendan also opens mitochondrial KATP 
channels [18] and exerts an organ- and, especially, cardioprotective effect in various settings 15 
[19,20]. At higher doses, the drug also acts as a phosphodiesterase type 3 (PDE3) inhibitor 
[1,12,21,22]. The effects of levosimendan are not impaired by the concomitant use of beta-
blockers [23].  
 
Levosimendan has been studied in several therapeutic applications, particularly in the 20 
management of acute HF (AHF) patients with low cardiac output [24,25] and in high-risk cardiac 
surgery [26,27]. Levosimendan has also shown preliminary positive effects in a range of other 
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conditions requiring inotropic support, including right ventricular failure, cardiogenic shock 
(CS), septic shock and Takotsubo cardiomyopathy [28]. 
 
Owing to its pharmacology, it has become apparent that levosimendan may also have 
applications in the setting of intensive care medicine. The conceptual framework for this wider 5 
use of levosimendan has been set out by Farmakis et al. [28] and is supported by an array of 
experimental and observational research [29–37] (see Box 1).  
 
This commentary identifies a range of clinical situations encountered in the intensive care unit 
(ICU) where levosimendan may offer clinical advantages, either as an adjunct to standard-of-10 
care therapies or as an alternative to conventional therapies (see Box 2). 
 
2. Hemodynamic support in cardiac critical care 
In severe AHF and CS, congestion and hypoperfusion lead to a systemic disorder that potentially 
affects all vital organs. Restoring adequate cardiac output and organ perfusion, and promoting 15 
decongestion, are therefore medical priorities during the early phase of treatment [38–40]. 
  
In AHF leading to tissue hypoperfusion, initial use of an inotrope is advocated [40,41]. Hence, 
inotropic support remains a cornerstone of AHF management in these critically ill patients, 
together with adequate fluid resuscitation (or depletion) and optimization of arterial pressure to 20 
suit the individual features of patients. 
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Reported rates of inotropic support in AHF management vary from 9% in an early US registry 
[42] to >30% in a later international registry [43] and 13% in the 2017 European Society of 
Cardiology (ESC) Heart Failure Long-Term Registry [44]. Robust secular trends in the use of 
inotropes are hard to identify from these fluctuations but dobutamine remains the most 
frequently used inotrope. 5 
The indication for inotropic support depends largely on the etiology; heading this hierarchy is 
CS, for which, by definition, virtually all patients are supported by at least one inotropic drug 
[45]. In septic shock, inotropic support is deployed according to current precepts of early goal-
directed therapy (EGDT); in recent EGDT trials, rates of inotrope use ranged from ≈15% for 
patients included in the intervention groups to usually <5% for those in the standard-of-care 10 
groups [46]. The prevalence of inotropic support at admission was 15–20% in a recent pragmatic 
multicenter trial of levosimendan in septic shock [37]. Inotropic support may also be considered 
in cases of obstructive shock, whilst waiting for the obstruction to be removed, but continuation 
after that point would be uncommon. 
 15 
Dobutamine is the first-line inotropic agent for resuscitating patients suffering from either severe 
AHF and low cardiac output syndrome [40] in CS [41,47] or septic shock [48] but its 
administration entails substantial addition of exogenous catecholamines to the endogenous ones 
already overproduced by the intense activation of the sympathetic autonomous nervous system. 
 20 
The resulting exacerbation of the beta-adrenergic pathway induces an increase in myocardial 
oxygen consumption via chronotropic and inotropic effects [49]. This catecholamine-induced 
myocardial oxygenation imbalance exacerbates myocardial ischemia [50,51], especially at the 
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level of the subendocardium [52]. Inter alia, excessive adrenergic stimulation is also established 
as a key factor in the pathophysiology of Takotsubo cardiomyopathy [53] and contributes 
substantially to some manifestations of the septic cardiomyopathies [54].  
Various large international registries relating to AHF and CS have documented higher rates of 
morbidity and mortality in patients treated with adrenergic inotropes than in severity-matched 5 
peers who did not receive catecholamines [42–45]; a recent meta-analysis of randomized clinical 
trials of dobutamine to treat severe (acute or chronic) HF likewise indicated an increased risk of 
mortality [55]. These observations, with others [56], are the basis of the European Society of 
Intensive Care Medicine AHF/CS guidance that “The use of these [inotropic/vasopressor] agents 
should, however, be restricted to the shortest possible duration and lowest possible dose to 10 
maintain perfusion pressure” [57] and the declaration in the ESC HF guidelines that “There is 
long-standing concern that [inotropes, especially those with adrenergic mechanisms] may 
increase mortality” [40]. 
 
In a randomized clinical trial involving patients with acutely exacerbated chronic HF, the PDE3 15 
inhibitor milrinone was shown to increase mortality in patients suffering from ischemic 
cardiomyopathy [58]: a similar finding was also reported in a recent large retrospective cohort 
study of intraoperative inotropic support in cardiac surgery [59]. These data indicate that 
milrinone (and, by extension, other PDE3 inhibitors) is not a fully satisfactory alternative to 
dobutamine. Similar reservations apply to dopamine [44,60] and epinephrine [45,61]. 20 
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The ‘decatecholaminization’ of the critically ill patient represents a new and still-evolving 
paradigm in the treatment of patients in the ICU [62,63]. One avenue for research in this area has 
been the evaluation of non-adrenergic vasoactive agents [64–66]. These include levosimendan, 
which offers positive cardiovascular effects (ventriculo-arterial recoupling, decongestion and 
cardiac protection against ischemia–reperfusion injury) as well as potentially advantageous 5 
ancillary effects on kidney function and diaphragm muscular fibers, as discussed later in this 
review. 
 
3. Levosimendan in cardiogenic shock 
Acute myocardial infarction (AMI) is the most common etiology of CS but CS may arise from 10 
any situation of acute, severe dysfunction in either ventricle of the heart. CS is relatively rare but 
often fatal [67]. 
  
The standard of care in CS consists of primary percutaneous coronary intervention (PCI) for 
AMI, fluid therapy, vasopressors, inotropes and, in the last resort, mechanical assistance [68]. 15 
Data from initial comparator studies indicate that levosimendan may be a useful addition to this 
regimen. 
 
Levosimendan may be a constructive alternative to conventional inotropes for the management 
of CS. In a trial of 22 consecutive AMI patients who developed CS after PCI, levosimendan (24 20 
µg/kg bolus, then 0.1 µg/kg/min for 24 h) attained the study endpoint of ≥30% increase in 
cardiac power output (CPO) consistently better than dobutamine (initial dose 5 µg/kg/min, with 
subsequent dose increases to reach the desired hemodynamic effect) despite a comparable 
reduction in pulmonary capillary wedge pressure [69] (Figure 1). (CPO is the product of cardiac 
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output and mean arterial pressure [MAP] and an indicator of cardiac contractility and 
ventricular–vascular coupling: in effect, it represents the pumping power of the heart and has 
been identified as the strongest predictor of survival in patients with CS [70].) 
 
Levosimendan also compared favorably with the PDE inhibitor enoximone in an exploratory 5 
open-label study of CS secondary to AMI, giving a small but significant advantage in death from 
multi-organ failure (p≈0.02) [71]. Beneficial hemodynamic effects were recorded in both groups, 
including enhancement of CPO, but these changes were achieved sooner with levosimendan than 
enoximone. There was a significant advantage with levosimendan in terms of fewer deaths from 
multi-organ failure (p<0.05). Use of dobutamine and norepinephrine in the levosimendan-treated 10 
patients was much lower than that in the enoximone group. It is plausible that part of the survival 
advantage seen with levosimendan may be attributable to a reduction in exposure to exogenous 
catecholamines. 
 
Notwithstanding these data, levosimendan is currently regarded as a salvage therapy in CS after 15 
dobutamine failure and before extracorporeal life support (ECLS). Any revision of this status 
will require well-designed randomized controlled studies [72]. Until then, the use of 
levosimendan may be considered in cases of low cardiac output associated with signs of 
hypoperfusion or deteriorating renal/liver function, especially if beta-blocker use is part of the 
clinical scenario.  20 
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Use of levosimendan is contraindicated in hypovolemia, which must be excluded using 
echocardiography and/or advanced monitoring and dynamic indices. Cardiac output monitoring 
(transpulmonary thermodilution or pulmonary artery catheterization in cases of associated right 
ventricular dysfunction) is highly recommended.  
 5 
Omitting a loading dose seems a rationale choice, while the maintenance infusion for a total 
duration of 24 h (0.05-0.2 mcg/kg/min) should be individually adjusted. After levosimendan is 
started, dobutamine may be weaned according to the hemodynamic and clinical response 
(generally after 2 h). As soon as possible, but after weaning of vasopressors, established chronic 
HF treatments should be (re-)introduced. 10 
 
In practice, systolic and diastolic dysfunction often coexist. The management of circulatory 
failure related to diastolic dysfunction in critical illness is largely supportive. Adequate fluid 
resuscitation is often followed by the administration of drugs with a positive lusitropic effect. 
Levosimendan has been shown to improve diastolic function [73] and filling and, importantly, it 15 
can be safely combined with beta-blockers, which represent one of the potential treatment 
modalities for diastolic dysfunction.  
 
4. Levosimendan in septic shock 
Sepsis is defined nowadays as an infection inducing dysfunction of at least one organ owing to a 20 
deregulated host inflammatory response [74]. In addition to intrinsic distributive shock due to 
vascular hyporeactivity and autonomic dysfunction, sepsis can also induce septic 
cardiomyopathy (SCM) with de novo AHF due to myocardial depression. Such complications 
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contribute to a sepsis mortality rate of ≈30% [74,75]. The prevalence of SCM among septic 
patients varies widely (from 20–60%), a state of affairs that reflects both the current lack of a 
common definition and the heterogeneity of the symptoms [75]. 
  
Inotropic support is endorsed for restoration of an adequate cardiac output and peripheral oxygen 5 
delivery [48]. In the absence of a fully evidence-based alternative, dobutamine remains the 
suggested first-line inotrope for those goals, despite observations that: (1) high levels of 
circulating catecholamines and adrenergic overstimulation contribute to the pathophysiology of 
SCM [54,76]; (2) the adrenergic response at the cardiomyocyte level is attenuated by 
downregulation of β-adrenergic receptors [77,78]; (3) adrenergic drugs have been associated 10 
with worse outcomes in a pooled network meta-analysis [36]; and (4) esmolol, a β1-receptor 
antagonist, seems to improve the outcome of severe SCM [78], especially in cases of persistent 
tachycardia [79].  
 
Proceeding
 
from the above points, assessment of levosimendan as an alternative inotropic drug in 15 
septic shock should address the following clinical goals and criteria. 
 
1. Dobutamine-sparing: reducing the high (toxic) levels of endogenous and pharmacological 
adrenergic stimulation and hence restoring a better myocardial oxygenation balance, 
particularly in the case of coronary artery disease (CAD) with potential catecholamine-20 
induced ischemia [51].  
2. Attenuation of multiple-organ failure (MOF): reducing the occurrence and/or severity of 
sepsis-induced MOF due to better regional blood flow distribution in addition to a global 
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increase in cardiac output, plus pleiotropic effects at the cellular and mitochondrial levels 
[28,80]. 
3. Inotropic rescue therapy: restoring inotropic responsiveness in cases of severely attenuated 
adrenergic response. 
4. Drug safety: replacing adrenergic inotropic drugs without tachyarrhythmia or any additional 5 
requirement for vasopressors. 
 
Experimental studies (mainly in animal models of peritonitis-induced septic shock) have 
demonstrated an improvement in survival, a reduction in the severity of MOF and anti-
inflammatory protective effects with levosimendan [80,81]. It must be acknowledged, however, 10 
that many of those studies were restricted to comparison versus placebo, not other inotropes.  
 
As regards clinical trials of levosimendan in septic shock, in a monocentric randomized 
controlled trial, a 24-h infusion of levosimendan (0.2 µg/kg/min) was compared with dobutamine 
(5 µg/kg/min) as inotropic support for patients with de novo severe SCM (n=28) and a left 15 
ventricular ejection fraction (LVEF) <45% despite 48 h of conventional standard-of-care 
treatment, including dobutamine [82]. Levosimendan use was associated with increases in 
cardiac output and pulmonary decongestion, without an increase in vasopressor requirements 
(owing to volume expansion), and with more favorable evolution of various MOF surrogates 
(lactate clearance, veno-arterial carbon dioxide gap, gut mucosal perfusion and renal function). 20 
Dobutamine did not materially alter any of these systemic or regional hemodynamic variables.  
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The findings of this study satisfy the clinical goals identified above and are, to that extent, 
promising regarding the potential of levosimendan in sepsis and SCM. However, this was a 
single study with several limitations and must be considered indicative, not definitive [83].  
 
The biological mechanisms underpinning this attenuation of MOF have been explored in 5 
subsequent clinical trials: levosimendan infusion has been shown to improve microcirculation 
perfusion [84], relieve mitochondrial oxidative stress [85] and restore the muscular 
lactate/pyruvate ratio [86]. Some of this research, plus additional small clinical trials of 
heterogeneous quality, has been incorporated into a meta-analysis [87] of the effects of 
levosimendan in septic shock versus standard inotropes (invariably dobutamine where specified). 10 
Findings from this exercise (seven studies, 249 patients) included a significant reduction in 
mortality in the levosimendan group without intergroup differences in MAP or norepinephrine 
usage.  
 
These clinical observations, together with a strong experimental background, led to the 15 
development of a large pragmatic multicenter randomized placebo-controlled trial of 
levosimendan in sepsis. This study – Levosimendan for the Prevention of Acute oRgan 
Dysfunction in Sepsis (LeoPARDS; ISRCTN12776039) – examined whether early 
administration of levosimendan (0.05–0.2 µg/kg/min for 24 h) could avert the onset of MOF in a 
broad population of septic shock patients (n=516) fulfilling the criteria for systemic 20 
inflammatory response syndrome due to infection, and requiring vasopressor therapy for at least 
4 h [37].  
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LeoPARDS did not fulfill the primary endpoint of a significant intergroup difference in mean 
daily Sequential Organ Failure Assessment score favoring levosimendan, and nor was mortality 
reduced. While prima facie disappointing, these findings should be considered in perspective. 
This was a relatively low-risk cohort; most patients were not suffering from either severe 
circulatory shock or severe SCM needing inotropic support. Moreover, the degree of renal 5 
replacement therapy already being undertaken before randomization was substantial and may 
have led to faster elimination of the study drug in 17% of patients in the intervention group. 
These reasons may have resulted in LeoPARDS lacking the necessary focus to identify an effect 
of levosimendan on the patients who could have benefitted. From a safety perspective, however, 
levosimendan infusion was broadly very well tolerated. 10 
  
The currently available clinical evidence in septic shock indicates that: (a) Levosimendan can 
successfully replace dobutamine in supporting severe de novo AHF due to SCM, with additional 
positive extra-cardiac effects owing to amelioration of MOF. These results need to be replicated 
on a larger scale; and (b) Indiscriminate use of levosimendan (i.e. without selecting severe cases 15 
of cardiovascular failure) to prevent the development of MOF is safe from a hemodynamic 
perspective but may confer no clinical benefit.  
 
In addition, however, recent data from patients in septic shock show ventriculo-arterial 
uncoupling due to either ventricular elastance reduction (as in SCM) or increased arterial 20 
elastance due to vasopressor therapy, or both: this is a situation in which cardiac mitochondrial 
function can be severely impaired and the oxygen metabolism altered [88]. No data are currently 
published on the effect of levosimendan on ventriculo-arterial coupling in septic shock, but this 
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matter merits research as the mechanism of action of levosimendan may contribute to the 
restoration of more normal coupling. 
 
Future investigations to refine the role of levosimendan in the management of septic shock 
should address (1) the severity of AHF (a priori, there is a case for reserving levosimendan for 5 
patients more likely to benefit from it, such as those with severely reduced LVEF or significant 
CAD [26,89]); and (2) the timing of the administration (under which heading, matters for 
attention include investigation of levosimendan as a first-use inotrope for severe SCM in order to 
optimize its positive cardioprotective effects as intimated from various lines of research, 
including randomized trials in cardiac surgery that recorded better outcomes with earlier 10 
administration [89–92]).  
 
5. Levosimendan and weaning from the ventilator 
About 10–20% of intubated patients in ICUs are difficult to wean from mechanical ventilation, 
resulting in increased morbidity, mortality and healthcare costs [93,94]. Part of this phenomenon 15 
may be attributable to the development of diaphragm weakness in intubated patients. Mechanical 
ventilation results in rapid loss of diaphragmatic force production [95–97]. In one recent study, 
half of patients (n=185) with diaphragmatic dysfunction failed weaning, half of whom died [98]. 
In addition, liberation from mechanical ventilation to spontaneous ventilation may dramatically 
increase left ventricular filling pressure and pulmonary artery pressure, especially in patients 20 
with pre-existing cardiac and/or pulmonary comorbidities. 
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The pathophysiology of muscle weakness in these patients is complex [99,100] but includes 
muscle fiber atrophy and reduced calcium sensitivity of the contractile proteins [101]. As 
respiratory muscle troponin resembles cardiac troponin, it is plausible that levosimendan may 
enhance muscular contractility in the same way that it enhances cardiac contractility. This 
supposition has support from in vitro data [102], experimental research [103] and a healthy 5 
volunteer study [104]. Positive effects were seen in both slow and rapid diaphragm muscle fibers 
[102,103]. 
 
Levosimendan has been compared with dobutamine in difficult-to-wean chronic obstructive 
pulmonary disease patients [105]. Levosimendan resulted in significantly greater inhibition of 10 
spontaneous ventilation-induced congestion caused by a rapid increase in pulmonary artery 
occlusion pressure. Similarly, mean pulmonary artery pressure increased to a lesser extent with 
levosimendan than with dobutamine. In a prospective observational study in ventilator-
dependent difficult-to-wean ICU patients with diminished LVEF (<40%), levosimendan 
improved cardiac contractility and oxygenation variables and increased the likelihood of 15 
separation from mechanical ventilation [93]. A study entitled the Effects of Levosimendan on 
Diaphragm Function in Mechanically Ventilated Patients (NCT01721434) coordinated by the 
University Medical Center, Nijmegen, The Netherlands is currently recruiting. 
 
6. Levosimendan and weaning from extracorporeal membrane oxygenation 20 
Veno-Arterial extracorporeal membrane oxygenation (VA ECMO) is increasingly used for short-
term management of refractory CS caused by AMI, myocarditis, cardiac surgical procedures in 
high-risk patients with reduced LVEF, refractory cardiac arrest and other conditions. In general it 
is reserved for situations where pharmacological support of the circulation is not able to restore 
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adequate cardiac output. In cases where there is sufficient recovery of myocardial function 
during VA-ECMO support, the phase of weaning starts by reducing blood flow through VA 
ECMO and thus increasing blood flow to the native heart chambers and pulmonary circulation, 
i.e. increasing the load imposed on both ventricles. In a large observational study, the rate of 
successful weaning in 4658 patients with CS was reported to be limited to 65.7% [106].  5 
A first report on levosimendan in the context of VA-ECMO weaning showed that pretreatment 
24 h before the start of weaning was associated with a 50% reduction in the need for inotropic 
and/or vasopressor support during or after weaning, as compared with a 100% requirement in the 
retrospective control group (n=11) (p<0.003) [107]. The weaning success rate was significantly 
higher with levosimendan (83.3% vs. 27.3%; p=0.0498); the difference in survival rate was 10 
substantial but not statistically significant (66.6% vs. 36.4%).  
In a recent retrospective analysis of 240 patients on VA ECMO after cardiovascular surgery, 
levosimendan was given during the first 24 h of ECMO support in 74.6% of cases [108]. The 
adjusted hazard ratio (HR) for failure of ECMO weaning with levosimendan was significantly 
improved versus control (HR 0.41; 95% confidence interval 0.22–0.80; p=0.008); furthermore, 15 
patients in the levosimendan group experienced lower 30-day mortality (p=0.016) and better 
long-term survival (Figure 2). Another study reported improvement in endothelial function after 
levosimendan infusion in the patients on VA ECMO, together with an improvement in cardiac 
function (i.e. an increase in cardiac output), facilitating weaning from ECMO [109]. Very recent 
data show that levosimendan enables weaning from ECLS without increasing norepinephrine 20 
requirements when compared with a control group receiving milrinone [110].  
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Most patients require inotropic drugs to support myocardial contractile function during weaning 
from VA ECMO and the limited clinical evidence currently available suggests that levosimendan 
offers some important advantages over other inotropes for this vulnerable period: no increase in 
myocardial oxygen consumption, a prolonged cardiovascular effect (days) and improvement in 
endothelial function.  5 
 
7. Levosimendan in pulmonary hypertension and right ventricular dysfunction 
Acute postoperative pulmonary hypertension is a rare but serious event after weaning from 
cardiopulmonary bypass and must be managed aggressively to avoid right ventricular failure 
[111,112]. The in-hospital mortality rate is high and may reach 70–75% [113,114]. Similar 10 
considerations apply in non-surgical ICUs where right ventricular dysfunction may emerge as a 
complication of acute respiratory distress syndrome [115]. 
 
The thin-walled right ventricle has poor tolerance for acute increases in afterload. Ventricular 
distension leads to severe compromise of contractility concomitant with an increase in oxygen 15 
consumption. Ventricular interdependence then implicates the left ventricle, leading to reduced 
filling, decreased cardiac output and oxygen delivery and decline in systemic perfusion pressure 
[116]. The pressure gradient for the perfusion of the right coronary artery drops as aortic pressure 
decreases and right ventricular pressure increases, leading to right ventricular ischemia [117].) 
 20 
Augmentation of right ventricular function with inotropic support is central to counteracting this 
vicious cycle. Levosimendan improves myocardial contractility, with a reduction in pulmonary 
vascular resistance [118]. In an experimental pressure load-induced model of right ventricular 
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failure, levosimendan improved right ventricular to pulmonary artery coupling more than 
dobutamine [119]. The treatment of acute right ventricular failure involves reversing the cause of 
the increased pulmonary vascular resistance while maintaining adequate MAP. To support 
adequate systemic arterial tone, a vasopressor is often required, while levosimendan helps to 
decrease pulmonary vascular resistance and filling pressures. 5 
 
Investigator-initiated studies have been performed in patients with right ventricular failure. In 
these, levosimendan reduced increased right ventricular afterload and improved right ventricular 
contractility and diastolic function [120–123].  
 10 
A recent meta-analysis demonstrated that levosimendan decreased systolic pulmonary pressure 
and pulmonary vascular resistance concomitant with an increase in right ventricular ejection 
fraction in patients suffering from acute right HF [124]. Much of the extant data comes from non-
cardiac surgery patients suffering acute onset of pulmonary hypertension and/or right ventricular 
dysfunction; data on levosimendan in acute right ventricular failure are sparse though 15 
encouraging [125].  
 
8. Levosimendan and renal function 
Evidence for a renal-protective action of levosimendan in preclinical experiments is persuasive 
but the clinical dataset supporting a renal-protective effect rests on a limited number of studies, 20 
many of them small and characterized by heterogeneities [126]. The results of those studies 
acquire significance only when pooled in meta-analyses [127–130] but, addressed in that way, 
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the findings are suggestive of a renal-protective effect of levosimendan in a range of cardiac low-
output states that may be pertinent to the ICU setting.  
 
Levosimendan has been compared with dobutamine in 88 patients with HF who required 
inotropic therapy [131]. Calculated glomerular filtration rate (cGFR) improved in response to 5 
levosimendan (0.1–0.2 µg/kg/min, with loading dose at the discretion of individual physicians) 
but was unchanged in patients who received dobutamine (5 µg/kg/min for at least 6 h, with 
subsequent dose alteration or extension beyond 24 h as judged necessary in individual cases). 
Complementary findings emerged from a placebo-controlled study in 66 patients hospitalized for 
decompensated HF and renal dysfunction, with a statistically significant improvement in cGFR 10 
in patients who received levosimendan (12 µg/kg optional loading dose, then continuous infusion 
at 0.05–0.2 µg/kg/min for 24 h). Peak effect was attained 3 days after a 24-h infusion and the 
effects persisted for up to 14 days [132]. Two open-label studies also reported reduction of serum 
creatinine levels in levosimendan-treated patients [133,134]. In a recent randomized study [135] 
on the effect of levosimendan on renal outcome in 90 cardiac surgery patients with chronic 15 
kidney disease and perioperative cardiovascular dysfunction, the authors reported a significant 
reduction in postoperative acute kidney injury (AKI) and a lower incidence of major 
complications in the levosimendan arm. 
 
What are the mechanisms behind the clinical observation that levosimendan seems to improve 20 
renal function in patients with AHF requiring inotropic support? Inodilators increase cardiac 
output and also potentially renal blood flow (RBF). It is not immediately evident, however, that 
an inodilator with renal vasodilating properties also increases GFR: it depends on its effect on 
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the longitudinal distribution of renal vascular resistance. Thus, theoretically, an inodilator that 
dilates the preglomerular resistance vessels (afferent arterioles) will, at a certain MAP, increase 
both RBF and GFR. On the other hand, an inodilator that preferentially causes vasodilation of 
the postglomerular resistance vessels (efferent arterioles) will increase RBF but cause a fall in 
GFR, due to a fall in the upstream glomerular hydraulic pressure. Finally, an inodilator that 5 
dilates both pre- and postglomerular resistance vessels will induce a pronounced increase in RBF 
with no change in GFR. Redfors et al. [136] showed in postcardiac surgery patients that low-
dose dopamine (2–4 µg/kg/min) induced a pronounced 40–50% increase in RBF with no effect 
on GFR, suggesting vasodilation of both pre- and postglomerular resistance vessels. 
Levosimendan, on the other hand, has been shown to increase both RBF and GFR after cardiac 10 
surgery, indicating that, in contrast to dopamine, levosimendan improves renal performance by 
means of preferential preglomerular vasodilation [137] (Figure 3). The major goal in the 
treatment of AKI is to increase GFR. There is, however, a close association between GFR and 
renal oxygen consumption [138], as any agent that increases GFR will also increase renal oxygen 
demand. Thus, an ideal inodilator to treat AKI would be one that increases both RBF and GFR. 15 
Such an agent will not only increase GFR but will also meet the increased renal metabolic 
demand by means of increased renal oxygen delivery. Bragadottir et al. [137] showed that the 
levosimendan-induced increase in GFR did not impair the renal oxygen supply/demand 
relationship, suggesting that levosimendan could be an interesting agent for treatment of AHF 
accompanied by impaired renal function in various clinical settings. In a recent double blind 20 
randomized clinical trial the same group recently showed that, in patients with chronic heart 
failure and renal impairment, levosimendan increases glomerular filtration rate to a greater extent 
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than dobutamine and thus may be the preferred inotropic agent for treating patients with the 
cardio-renal syndrome [139] 
 
Complementary findings were reported from a placebo-controlled study by Fedele et al. 
[139140] in patients with acute decompensated HF and moderate renal impairment 5 
(NCT00527059). Yilmaz et al. [126] have speculated on the likely contribution of KATP channel-
opening effects of levosimendan in vascular smooth muscle to a direct renal-protective effect of 
levosimendan separate from, and additional to, its effects via improved cardiac function and 
systemic hemodynamics. Observations on the significance of levosimendan-mediated 
vasodilatation and decongestion have been made by Damman and Voors [140141]. 10 
 
Diuretic resistance in HF patients is a common problem. One treatment option could be the 
administration of levosimendan. This might be a good option before the more aggressive 
implementation of ultrafiltration [141142]. 
 15 
 
9. Other settings 
Is to be noticed that the HFA-ESC Task Force on Takotsubo syndrome [142143] advocates 
levosimendan as the single form of inotropic support in cases of unavailable ECLS. Case reports 
are encouraging [143144] and the pathophysiology is conceptually a good fit to the properties of 20 
levosimendan.  
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10. Conclusions 
Levosimendan has been demonstrated to have potential utility in a range of critical illness 
scenarios. It must be acknowledged, however, that in each sphere of application the evidence is 
incomplete or indicative rather than conclusive and further clinical evaluation will be needed to 
substantiate the case for levosimendan and to refine the patient categories and dosage schedules 5 
likely to be associated with the greatest clinical benefit . 
 
Having levosimendan a vasodilatory effect, its dosage should be guided in part by following the 
blood pressure of the patient (as recommended by the indication for use), with bolus omitted or 
used only if SBP is ≥100 mm Hg [145] (see Box 3). Meta-analysis of 45 randomized controlled 10 
trials in cardiac surgery or cardiology identifies an infusion rate range of 0.05–0.2 mg×kg-1×min-
1
, with some indications that both lower rates (≤0.1 mg×kg-1×min-1) and omission of bolus dose 
may confer greater long-term survival advantages over higher doses and use of bolus [146]. The 
presence of a long-lived metabolite is associated with the persistence of the hemodynamic effects 
of levosimendan [147] 7-10 days after a single 24-hour infusion of levosimendan. The inodilator 15 
levosimendan is mainly used for its hemodynamic effects, and the longer action of its active 
metabolite is fully consistent with the pharmacologic effects observed in the beginning of the 
treatment: no increase in the rate of adverse events was observed after the 24-hour infusion of 
levosimendan [148]. 
 20 
The regulatory Phase IIb-III clinical trials program on the efficacy and safety of 
levosimendan in acute heart failure completed in 2005 (see complete trial list in Pollesello et al. 
[149]) did not give an unequivocal answer to the question whether the short term use of 
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levosimendan lowers long term mortality in patients hospitalized for decompensated acute heart 
failure irrespectively to its etiology and to the use of co-medications during the pre-, peri-, and 
post-acute phase. Some trials showed a significant improvement in survival, some (the larger 
ones) not, but the bulk of evidence did overall support the efficacy and safety of the drug, and a 
market authorization was granted in over 60 countries, with the notable exception of the U.S.A. 5 
and the U.K. The regulatory studies included a broad variability of patients, both as it regards the 
etiologies (e.g. de novo vs chronic decompensated HF), the monitoring (e.g. invasively vs non-
invasively), the time of treatment (e.g. early during hospitalization vs late), and the co-
medications (e.g. beta-blockade vs non beta-blockade). When more homogeneous groups of 
patients are considered (see analysis by Kivikko et al. [150]) the short term effects of 10 
levosimendan on symptoms, hemodynamics, and neurohormons, are accompanied to a 
significant long-term effect on survival. As it regards the clinical studies in the ICU field, the 
same pattern can be seen when comparing the large LEOPARDS study [37] to the many 
previous smaller studies on the use of levosimendan in septic shock [151]: when the patients are 
poorly defined, the results are so spread that not any statistical significance can be reached. 15 
Therefrom originates the conundrum: in the field of ICU, the large studies needed for ‘evidence 
based medicine’ necessarily include a broad spectrum of patients and the effects of drugs can be 
easily masked in the statistical analyses, while smaller (often monocentric) studies can spot 
significant positive drugs effects due to the good selection of patients, but their results will 
remain necessarily limited. We hereby propose possible solutions for a way out. 20 
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Central to future investigations must be the identification of robust and relevant endpoints. An 
improvement in survival/mortality may be plausible in cases where levosimendan substitutes for 
an adrenergic inotrope with a documented propensity to increase mortality. In other settings, 
however, it is not obvious that a mortality gain can be assumed nor is it certain that any such 
gain, welcome as it would be, would be the most pertinent measurement of any treatment effect. 5 
It is, moreover, unclear how far into the future any survival benefit from a short-term 
intervention in what is likely to be a complex and multifaceted medical crisis should reasonably 
be expected to extend. None of the conventional adrenergic inotropic drugs have in fact been 
associated with improvements in hard endpoints such as mortality and there are many indications 
to the contrary. The reported experience of Distelmaier et al. [108] (Figure 2) is encouraging 10 
with regard to the prospect of a long-term advantage in the sphere of weaning from ECMO but 
may not be similarly applicable in other situations and is in any case in need of corroboration.  
  
We consider, for these reasons, that an overemphasis on crude mortality may not be the most 
informative approach to future clinical trials of levosimendan. We are inclined towards the 15 
position of Schumann and colleagues [72], who have advocated the evaluation of EGDT in CS 
and low-cardiac output syndrome, arguing that refining the best therapeutic strategy is more 
constructive than trying to identify the ‘best’ drug for hemodynamic support. Similarly, 
identifying the most effective regimen for, say, weaning from ECMO or the management of 
pulmonary hypertension needs to take a wider view of the issue than simply focusing too closely 20 
on the impact of a single intervention perhaps delivered for a short period of time. The adoption 
of hierarchical endpoints in clinical trials of levosimendan in HF (e.g. LEODOR; 
NCT03437226) is an innovation that may also find applications in future clinical trials in the 
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ICU setting and may enable a more nuanced appraisal of the impact of levosimendan in those 
situations.  
 
The concepts of ‘enriched enrollment’, ‘-omics profile feeding new biomarkers’ and ‘accurate 
prognostication’ are key to precision medicine and may be expected to contribute to improving 5 
the power, robustness and information yield from future trials [144]. 
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 5 
BOX 1: Expected effects of Levosimendan in Intensive Care Unit Settings 
 
• General hemodynamic support 
• Increased ejection fraction and cardiac index without increase of oxygen consumption 
• Periferal vasodilation and reduction of tissues and organ hypoperfusion 10 
• Increased GFR and renal function 
• Decrease in need for cathecolamines 
• Sustained effects 
• No increase of long-term mortality 
 15 
BOX 2: Intensive Care Unit Settings in which the use of Levosimendan has been described 
 
• Cardiogenic shock 
• Septic shock 
• Weaning from ventilator 20 
• Weaning from extracorporeal membrane oxygenation 
• Pulmonary hypertension and right ventricular dysfunction  
• Need for hemidynamic support in patients with diuretic resistance 
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BOX 3: recommended dosage of levosimendan when used in Intensive Care Unit Settings 
• Levosimendan dosage should be guided by following the blood pressure; 
• Bolus should be omitted or used only if SBP is ≥100 mm Hg;  
• An infusion rate range of 0.05–0.2 mg×kg-1×min-1 starting at 0,1 mg×kg-1×min-1 and up-or 
down-titrated to the doses which gives hemodynamic stability while avoiding adverse effects 5 
such hypotension and/or arrhythmias; 
• Hypovolaemia and hypokalemia should be avoided before and during treatment; 
• The presence of a long-lived metabolite is associated with the persistence of the 
hemodynamic effects of levosimendan 7-10 days after a single 24-hour infusion of 
levosimendan; 10 
• levosimendan is mainly used for its hemodynamic effects, and the longer action of its active 
metabolite is fully consistent with the pharmacologic effects observed in the beginning of the 
treatment: no increase in the rate of adverse events (hypotension and/or arrhythmia) is 
observed after the 24-hour infusion of levosimendan. 
 15 
Legends 
 
Figure 1. Changes in cardiac power output during infusion of levosimendan (○) and dobutamine 
(●) in patients with acute myocardial infarction re-vascularized by percutaneous coronary 
intervention and who developed cardiac shock. Data points are mean ± standard deviation. 20 
*p<0.05 (Student’s t-test). Data from García-González et al. [69]. 
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Figure 2. Confounder-adjusted long-term survival (levosimendan vs control, p=0.04) in 240 
patients weaned from extracorporeal membrane oxygenation. Levosimendan was administered 
within the first 24 h after initiation of ECMO therapy, at a standard dose of 12.5 mg in 24 h. Data 
from Distelmaier K et al. [108] . 
 5 
 
Figure 3. Differential effects of levosimendan (0.1 µg/kg/min) and dopamine (2 µg/kg/min) on 
renal blood flow (RBF) and glomerular filtration rate (GFR) in 30 post-cardiac surgery patients. 
The experimental procedure started 4–6 hours after surgery in the ICU during propofol sedation 
and mechanical ventilation. Cardiac index (CI) was increased by ≈20% by both drugs. From 10 
Bragadottir et al. [137].  
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